1. Association Between Reduced Levels of Alkaline Phosphatase and Survival Times of Patients With Primary Sclerosing Cholangitis 
Lina Lindström, Rolf Hultcrantz, Kirsten Muri Boberg, Ingalill Friis–Liby, Annika Bergquist 
Clinical Gastroenterology and Hepatology 
Volume 11, Issue 7, Pages (July 2013)
DOI: /j.cgh
Copyright © 2013 AGA Institute Terms and Conditions

2. Figure 1
Kaplan–Meier survival curve of 198 patients enrolled in the 5-year Scandinavian UDCA trial in 1996 randomized to UDCA vs placebo with extended follow-up in 2009/2010 (P = .77, log-rank test).
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions

3. Figure 2
Kaplan–Meier analysis of end point–free survival in UDCA-treated patients with a biochemical response (ie, normal or ≥40% reduction in ALP after 1 year in the trial) vs nonresponders (P = .033, log-rank test).
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions

4. Figure 3
Kaplan–Meier analysis of end point–free survival in biochemical responders vs nonresponders, regardless of treatment with UDCA (P = .0001, log-rank test).
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions

5. Figure 4
Kaplan–Meier analysis of end point–free survival in all patients stratified by treatment with UDCA and biochemical response (P = .001, log-rank test).
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions